Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dalian Yalifeng Biopharmaceutical Begins Influenza A/H1N1 Vaccine Production

This article was originally published in PharmAsia News

Executive Summary

Dalian Yalifeng Biopharmaceutical has started to produce China's first batch of Influenza A/H1N1 vaccine. Upon receiving the H1N1 virus strain from WHO, the company has begun inoculation of chicken eggs for experiments. The vaccine production procedure will begin with virus amplification, followed by extraction of its surface antigen to produce the antibody. The first batch of six million doses is expected to be produced in Dalian by the end of September. The city's FDA will closely monitor the entire production process to ensure compliance with WHO standards. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071898

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel